Good news has been scarce for this beaten-down drugmaker.

In the latest close session, Pfizer (PFE) was up +1.67% at $28.55. The stock outperformed the S&P 500, which registered a daily gain of 0.72%. Elsewhere, the Dow saw an upswing of 0.48%, while the ...

Pfizer is behind Eli Lilly and Novo Nordisk in the GLP-1 race, but long-term investors shouldn't count the company out.

Pfizer Inc. shares ticked up modestly Tuesday as investors weighed fresh positive oncology data against the pharmaceutical ...

A big dividend can’t hide the growth problem at Pfizer (PFE), one of the world’s largest pharmaceutical companies. Pfizer has ...

Pfizer has quietly built momentum in 2026 and Guggenheim just raised its price target to $36 while reiterating a Buy rating.

Pfizer stock reached a 52-week high, hitting 27.99 USD, marking a significant milestone for the pharmaceutical giant. Over the past year, Pfizer has experienced a positive traject ...

Shares of Pfizer Inc. PFE advanced 1.12% to $28.08 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 2.91% to 6,528.52 and ...

Pfizer has reached a transition point following declines of some of its biggest blockbusters. The pharma giant is paving the way to growth through new products and acquisitions. 10 stocks we like ...

Pfizer (NYSE: PFE) recently experienced yet another setback. The drugmaker has been posting disappointing financial results for several years, and its latest quarterly update sent its stock price down ...

They aren't just "pandemic stocks." ...